Hussein Mossawi-Al

BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Beta cell-targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices.

Beta cell-targeted PD-1 agonist inhibits cell-mediated autoimmunity in pancreas tissue slices.

Journal: Science advances

Published: April 01, 2026

State of the art and novel treatments in psoriatic arthritis.

State of the art and novel treatments in psoriatic arthritis.

Journal: Best practice & research. Clinical rheumatology

Published: January 31, 2026

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices.

Inhibition of cell-mediated immunity in type 1 diabetes by beta cell-targeted PD-1 agonists in pancreas tissue slices.

Journal: bioRxiv : the preprint server for biology

Published: November 24, 2025

Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn's disease.

Epigenetic modulation of stromal cell states underpins pathological tissue niches in Crohn's disease.

Journal: Nature immunology

Published: August 07, 2025

Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus.

Long-Term Anifrolumab Treatment Normalizes Hematologic Parameters and Several Serologic Markers in Patients With Systemic Lupus Erythematosus.

Journal: ACR open rheumatology

Published: July 28, 2025

Reassessing antimalarial use in long-term SLE clinical trials - Authors' reply.

Reassessing antimalarial use in long-term SLE clinical trials - Authors' reply.

Journal: The Lancet. Rheumatology

Published: June 12, 2025

Cell-targeted PD-1 agonists are potent NK-cell inhibitors.

Cell-targeted PD-1 agonists are potent NK-cell inhibitors.

Journal: Frontiers in immunology

Published: June 03, 2025

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial.

Journal: RMD open

Published: May 20, 2025

High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging.

High prevalence of MASLD in psoriasis and psoriatic arthritis assessed with multiparametric magnetic resonance imaging.

Journal: Rheumatology (Oxford, England)

Published: March 25, 2025

Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL-17 treatment: a clinical case.

Liver fibro-inflammation in psoriatic arthritis with MASLD improved by anti-IL-17 treatment: a clinical case.

Journal: Rheumatology (Oxford, England)

Published: March 25, 2025

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial.

Journal: The Lancet. Rheumatology

Published: August 30, 2024

Publisher Correction: Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus.

Publisher Correction: Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus.

Journal: Nature

Published: July 26, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026